계명대학교 의학도서관 Repository

The Safety of Intra-arterial Tirofiban during Endovascular Therapy after Intravenous Thrombolysis

Metadata Downloads
Author(s)
S.H. JangS.-I. SohnH. ParkS.-J. LeeY.-W. KimJ.M. HongC-H. KimJ.W. ChoiD.-H. KangY.-S. KimY.-H. HwangJ.S. LeeJ.-H. Hong
Keimyung Author(s)
Kim, Chang Hyun
Department
Dept. of Neurosurgery (신경외과학)
Journal Title
AJNR Am J Neuroradiol
Issued Date
2021
Volume
42
Issue
9
Abstract
BACKGROUND AND PURPOSE:
The safety and efficacy of tirofiban during endovascular therapy in patients undergoing intravenous thrombolysis with recombinant IV tPA remain unclear. This study aimed to investigate the safety and efficacy of intra-arterial tirofiban use during endovascular therapy in patients treated with IV tPA.

MATERIALS AND METHODS:
Using a multicenter registry, we enrolled patients with acute ischemic stroke who underwent endovascular therapy. Safety outcomes included postprocedural parenchymal hematoma type 2 and/or thick subarachnoid hemorrhage, intraventricular hemorrhage, and 3-month mortality. Efficacy outcomes included the successful reperfusion rate, postprocedural reocclusion, and good outcomes at 3 months (mRS scores of 0–2). The tirofiban effect on the outcomes was evaluated using a multivariable analysis while adjusting for potential confounders.

RESULTS:
Among enrolled patients, we identified 314 patients with stroke (279 and 35 patients in the no tirofiban and tirofiban groups, respectively) due to an intracranial artery occlusion who underwent endovascular therapy with intravenous thrombolysis. A multivariable analysis revealed no association of intra-arterial tirofiban with postprocedural parenchymal hematoma type and/or thick subarachnoid hemorrhage (adjusted OR, 1.07; 95% CI, 0.20–4.10; P = .918), intraventricular hemorrhage (adjusted OR, 0.43; 95% CI, 0.02–2.85; P = .467), and 3-month mortality (adjusted OR, 0.38; 95% CI, 0.04–1.87; P = .299). Intra-arterial tirofiban was not associated with good outcome (adjusted OR, 2.22; 95% CI, 0.89 –6.12; P = .099).

CONCLUSIONS:
Using intra-arterial tirofiban during endovascular therapy after IV tPA could be safe.
Keimyung Author(s)(Kor)
김창현
Publisher
School of Medicine (의과대학)
Citation
S.H. Jang et al. (2021). The Safety of Intra-arterial Tirofiban during Endovascular Therapy after Intravenous Thrombolysis. AJNR Am J Neuroradiol, 42(9), 1633–1637. doi: 10.3174/ajnr.A7203
Type
Article
ISSN
1936-959X
Source
http://www.ajnr.org/content/42/9/1633.long
DOI
10.3174/ajnr.A7203
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/43922
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.